100940-65-6
100940-65-6 结构式
基本信息
L-Valine, N-[(3-hydroxy-2-quinolinyl)carbonyl]-D-seryl-(2S)-2-piperidinecarbonylglycyl-N-methylglycyl-N-methyl-, bimol. (5→1'3),(5'→13)-dilactone
3-hydroxy-N-[23-[(3-hydroxyquinoline-2-carbonyl)amino]-8,11,28,31-tetramethyl-2,6,9,12,15,22,26,29,32,35-decaoxo-7,27-di(propan-2-yl)-5,25-dioxa-1,8,11,14,21,28,31,34-octazatricyclo[34.4.0.0^{16,21}]tetracontan-3-yl]quinoline-2-carboxamide
常见问题列表
|
Traditional Cytotoxic Agents
|
Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for
Bacillus subtilis
(Rec
+
) A22508-2,
B. subtilis
(Rec
-
) A22509-2-2,
Staphylocccus aureus
209P-A9497,
S. aureus
(echinomycin-resistant) A9628,
Streptococcus faecalis
A96 1 1,
Escherichia coli
A151 19 and
E. coli
(actinomycin-sensitive) A21780 (AS-19), respectively.
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC
50
values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively.
Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice.
| Animal Model: | CDF1 female mice injected with leukemia P388 cells |
| Dosage: | 0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 5 days |
| Result: | Was moderately active in vivo against leukemia P388 in mice. |